Accordingly, we investigated the effect of the SGLT2 inhibitor canagliflozin on steatohepatitis and NASH-related hepatocarcinogenesis in the STAM mouse model of diabetes and NASH/cirrhosis/HCC. This evidence concerns the gene SLC5A2 and Cirrhosis.